Relievant Medsystems Acquisition, Valuation, Funding & Investors

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.

Synchron is a neurotechnology company advancing brain-computer interfaces through its endovascular Stentrode device. Delivered via catheter to the brain's blood vessels, it records neural signals for controlling external devices like prosthetics and computers. Brooklyn-headquartered, Synchron conducts clinical trials in Australia and the United States targeting paralysis patients.

Umoja Biopharma engineers in vivo CAR T-cell therapies that reprogram patients' T cells to attack solid tumors and hematological malignancies resistant to existing treatments. Seattle-headquartered, the company advances its AlloVector platform for localized immune cell activation without ex vivo manipulation. Partnerships with Biogen and Takeda support clinical progression in oncology pipelines targeting glioblastoma and other cancers.

RefleXion Medical is a developer of biology-guided radiotherapy systems for cancer treatment. Hayward-headquartered in California, RefleXion's X1 machine delivers stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT platform uses real-time PET imaging to target metastatic tumors with subsecond precision. RefleXion raised over $380 million in funding from investors including Sofinnova and Temasek.

LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.

AcuityMD is a software platform that aggregates clinical utilization data to accelerate medical device commercialization for orthopedics and spine companies. Boston-headquartered, it analyzes procedure volumes and surgeon preferences from electronic health records across U.S. hospitals. The platform equips sales teams with market intelligence on over 10 million procedures, enabling targeted account planning and evidence-based launches.

BenevolentAI is a London-headquartered clinical-stage company using artificial intelligence for drug discovery, listed on Euronext Amsterdam under BAI. Its platform supports 13 named programs and over 10 exploratory ones, with collaborations including AstraZeneca on respiratory and cardiovascular diseases. Facilities in Cambridge and New York enable wet-lab validation of AI-generated candidates.

Cornerstone Robotics is a Shenzhen-based developer of surgical robots enhancing minimally invasive procedures in Chinese hospitals. The company produces the Toumai system for laparoscopic surgeries, approved by NMPA for colorectal and urology applications. Cornerstone Robotics partners with tertiary hospitals in Beijing and Shanghai for clinical trials and deployments.

Dental Monitoring is a Paris-headquartered teledentistry company founded in 2014 offering AI-powered remote monitoring for orthodontic treatments. Its app enables patients to scan teeth via smartphone, analyzed by algorithms for 200-plus clinical criteria. The firm employs over 400 staff across Europe, the United States, Australia, Hong Kong, and Singapore, serving 3 million patients globally.

OrCam Technologies is a Tel Aviv-based developer of wearable visual aid devices. The OrCam MyEye 2.0 clips onto eyeglasses and reads text aloud, recognizes faces, identifies products, and detects colors via AI-powered camera. Founded in 2010, the company serves people with vision impairment, dyslexia, and reading difficulties. OrCam partners with retailers like Boots and distributes globally.

SiBionics is a Chinese medical device company developing AI-based devices for chronic disease management, including its GS1 and GS3 continuous glucose monitoring (CGM) systems for people with diabetes. Its GS3 sensor is described as the world's thinnest CGM and has earned CE Mark approval alongside other products in its lineup, placing the company in the competitive global CGM market alongside established international players.

Embark is a Boston-based canine genetics company offering DNA testing kits. The platform analyzes over 200,000 genetic markers using CLIA-certified SNP chips to screen for breed, health risks, traits, and preventive care recommendations, contributing to veterinary research on nutrition and diseases.

Hyperice is a Carlsbad, California-headquartered company manufacturing percussion massage devices, compression boots, and thermal wearables for athletic recovery. Its Hypervolt line delivers targeted vibration therapy up to 3,200 percussions per minute, adopted by over 400 professional sports teams including NBA's Los Angeles Lakers and NFL's New England Patriots. Founded in 2012, Hyperice expands into consumer fitness with Normatec recovery systems used in Olympic training facilities worldwide.

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Ultragreen Ai Ltd is engaged in the sales of Indocyanine Green (ICG) pharmaceutical products and cardiology Picture Archiving and Communication System (PACS) software and associated products and services. It provides a fluorescence imaging ecosystem designed to support surgeons with real-time perfusion data and visualization capabilities. The company is organised into business units based on its products and services and operates in (a) the Diagnostic Green (DxG) - Americas segment; (b) the DxG - Rest of the World segment; and (c) the UltraLinQ segment. The company generates the maximum of its revenue from the the DxG - Rest of the World segment, which focuses on the sales of ICG vials and related pharmaceutical products.